Amphastar Pharmaceuticals, INC Form 4 insider transactions

Amphastar Pharmaceuticals, Inc. Director Diane G. Gerst has acquired 5,122 restricted stock units and 11,402 stock options, aligning her interests with shareholders.

Amphastar Pharmaceuticals Director Richard K. Prins reported the acquisition of 5,122 restricted stock units and 11,402 stock options as part of his compensation on June 2, 2025.

Amphastar Pharmaceuticals, Inc. Director Floyd F. Petersen reported the sale of 500 shares of common stock and the acquisition of 5,122 restricted stock units and 11,402 stock options on June 2, 2025.

Amphastar Pharmaceuticals, Inc. Director Michael A. Zasloff reported the acquisition of 5,122 restricted stock units and 11,402 stock options as part of compensation, aligning his interests with shareholders.

William J. Peters, CFO, EVP & Treasurer of Amphastar Pharmaceuticals, reports disposition of shares to cover tax obligations related to vesting of restricted stock units.

Floyd F. Petersen, a director at Amphastar Pharmaceuticals, sold 500 shares of common stock at an average price of $24.0829 on May 1, 2025, under a pre-arranged trading plan.

Floyd F. Petersen, a director at Amphastar Pharmaceuticals, sold 500 shares of common stock on April 1, 2025, under a pre-arranged 10b5-1 trading plan.

Senior EVP Zhou Rong of Amphastar Pharmaceuticals reports disposing of shares to cover tax liabilities related to vesting restricted stock units.

Jack Y. Zhang and Mary Z. Luo, key executives at Amphastar Pharmaceuticals, exercised stock options and sold shares to cover exercise costs and tax liabilities.

Yakob Liawatidewi, EVP Corp Admin Center at Amphastar Pharmaceuticals, reports disposition of shares to cover tax liabilities related to vesting of restricted stock units.

William J. Peters, CFO, EVP & Treasurer of Amphastar Pharmaceuticals, sold shares to cover tax liabilities related to vesting restricted stock units.

Senior EVP Rong Zhou reports the acquisition of stock options and restricted stock units in Amphastar Pharmaceuticals.

Yakob Liawatidewi, EVP Corp Admin Center at Amphastar Pharmaceuticals, reports acquisition of shares and options.

William J. Peters, CFO, EVP & Treasurer of Amphastar Pharmaceuticals, reports the acquisition of restricted stock units and stock options.

Amphastar Pharmaceuticals' CEO Jack Y. Zhang and COO Mary Z. Luo receive stock options and restricted stock units (RSUs) as part of their compensation.

Senior EVP Rong Zhou disposed of 1,354 shares of Amphastar Pharmaceuticals to cover tax liabilities related to vesting restricted stock units.

William J. Peters, CFO, EVP & Treasurer of Amphastar Pharmaceuticals, disposed of 2,141 shares of common stock on March 6, 2025, to cover tax liabilities related to vesting restricted stock units.

Yakob Liawatidewi, EVP Corp Admin Center at Amphastar Pharmaceuticals, reports the withholding of 1,141 shares to cover tax liabilities related to vesting restricted stock units.

CEO Jack Y. Zhang and related parties report disposals of Amphastar Pharmaceuticals stock to cover tax liabilities from vesting restricted stock units.

Director Floyd F. Petersen sold 1,000 shares of Amphastar Pharmaceuticals (AMPH) common stock at an average price of $27.9863 on March 6, 2025, according to a Form 4 filing.

Rong Zhou, Senior EVP at Amphastar Pharmaceuticals, disposed of 1,121 shares to cover tax liabilities related to vesting restricted stock units.

Yakob Liawatidewi, EVP Corp Admin Center at Amphastar Pharmaceuticals, reports the withholding of 963 shares to cover tax liabilities related to vesting restricted stock units.

CEO Jack Y. Zhang reports disposition of Amphastar Pharmaceuticals stock to cover tax liabilities related to vesting of restricted stock units.

William J. Peters, CFO, EVP & Treasurer of Amphastar Pharmaceuticals, reports exercising stock options and selling shares under a 10b5-1 trading plan.

A recent SEC filing reveals that a senior executive at Amphastar Pharmaceuticals exercised stock options and sold shares on December 12th and 13th, 2024.

A recent SEC filing reveals that an Amphastar Pharmaceuticals executive, Prins Richard K, sold 10,000 shares and exercised options for 10,000 shares.

A Form 4 filing reveals that a senior executive at Amphastar Pharmaceuticals exercised stock options and sold shares on November 12, 2024.

Director Richard K. Prins of Amphastar Pharmaceuticals executed multiple transactions involving company stock, including option exercises, sales, and a gift.

Amphastar Pharmaceuticals' CEO and COO transferred 125,000 shares each of common stock as gifts, resulting in changes to their beneficial ownership.

Yakob Liawatidewi, EVP Corp Admin Center at Amphastar Pharmaceuticals, reports exercising stock options and selling shares under a pre-arranged 10b5-1 trading plan.